PCSK6 and Familial prostate cancer: The similarity between previously obtained PACE4 molecular inhibition, (i.e., PACE4 shRNA-silenced LNCaP cells) and the pharmacologic inhibition obtained from the systemic administration of the ML-peptide analog, provides evidence for the use of PACE4 peptidomimetic analogs as a potential drug for a novel therapeutic approach for prostate cancer.